{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T15:30:19Z","timestamp":1795015819125,"version":"4.10.1"},"reference-count":67,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A challenge when targeting T-cell lymphoma with chimeric antigen receptor (CAR) T-cell therapy is that target antigens are often shared between T cells and tumor cells, resulting in fratricide between CAR T cells and on-target cytotoxicity on normal T cells. CC chemokine receptor 4 (CCR4) is highly expressed in many mature T-cell malignancies, such as adult T-cell leukemia\/lymphoma (ATLL) and cutaneous T-cell lymphoma (CTCL), and has a unique expression profile in normal T cells. CCR4 is predominantly expressed by type-2 and type-17 helper T cells (Th2 and Th17) and regulatory T cells (Treg), but it is rarely expressed by other T helper (Th) subsets and CD8+ cells. Although fratricide in CAR T cells is generally thought to be detrimental to anticancer functions, in this study, we demonstrated that anti-CCR4 CAR T cells specifically depleted Th2 and Tregs, while sparing CD8+ and Th1\u00a0T cells. Moreover, fratricide increased the percentage of CAR+ T cells in the final product. CCR4-CAR T cells were characterized by high transduction efficiency, robust T-cell expansion, and rapid fratricidal depletion of CCR4-positive T cells during CAR transduction and expansion. Furthermore, mogamulizumab-based CCR4-CAR T cells induced superior antitumor efficacy and long-term remission in mice engrafted with human T-cell lymphoma cells. In summary, CCR4\u2013depleted anti-CCR4 CAR T cells are enriched in Th1 and CD8+ T cells and exhibit high antitumor efficacy against CCR4\u2013expressing T-cell malignancies.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008327","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T13:25:14Z","timestamp":1681478714000},"page":"3416-3430","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":53,"title":["Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma"],"prefix":"10.1182","volume":"7","author":[{"given":"Keisuke","family":"Watanabe","sequence":"first","affiliation":[{"name":"1Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"},{"name":"2Division of Cancer Immunology, National Cancer Center Research Institute, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Gomez","sequence":"additional","affiliation":[{"name":"1Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichiro","family":"Kuramitsu","sequence":"additional","affiliation":[{"name":"1Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Siurala","sequence":"additional","affiliation":[{"name":"1Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Da","sequence":"additional","affiliation":[{"name":"1Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4272-515X","authenticated-orcid":false,"given":"Sangya","family":"Agarwal","sequence":"additional","affiliation":[{"name":"1Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Decheng","family":"Song","sequence":"additional","affiliation":[{"name":"1Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9725-6277","authenticated-orcid":false,"given":"John","family":"Scholler","sequence":"additional","affiliation":[{"name":"1Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2891-5793","authenticated-orcid":false,"given":"Antonia","family":"Rotolo","sequence":"additional","affiliation":[{"name":"3Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8711-629X","authenticated-orcid":false,"suffix":"Jr.","given":"Avery D.","family":"Posey","sequence":"additional","affiliation":[{"name":"1Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"},{"name":"3Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA"},{"name":"4Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain H.","family":"Rook","sequence":"additional","affiliation":[{"name":"5Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Haun","sequence":"additional","affiliation":[{"name":"5Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[{"name":"1Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"},{"name":"3Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA"},{"name":"6Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina M.","family":"Young","sequence":"additional","affiliation":[{"name":"1Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0241-3557","authenticated-orcid":false,"given":"Carl H.","family":"June","sequence":"additional","affiliation":[{"name":"1Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"},{"name":"3Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA"},{"name":"7Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"issue":"1","key":"2023072117502244100_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/intimm\/dxu079","article-title":"CCR4 and its ligands: from bench to bedside","volume":"27","author":"Yoshie","year":"2015","journal-title":"Int Immunol"},{"issue":"10 Pt 1","key":"2023072117502244100_bib2","first-page":"3625","article-title":"Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: its close association with skin involvement and unfavorable outcome","volume":"9","author":"Ishida","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2023072117502244100_bib3","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood.V99.5.1505","article-title":"Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T\u00a0cells","volume":"99","author":"Yoshie","year":"2002","journal-title":"Blood"},{"issue":"5","key":"2023072117502244100_bib4","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2009-11-251926","article-title":"Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors","volume":"116","author":"Campbell","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2023072117502244100_bib5","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.V96.2.685","article-title":"Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma","volume":"96","author":"Jones","year":"2000","journal-title":"Blood"},{"issue":"3","key":"2023072117502244100_bib6","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12185-010-0513-0","article-title":"Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma","volume":"91","author":"Asano","year":"2010","journal-title":"Int J Hematol"},{"issue":"3","key":"2023072117502244100_bib7","first-page":"605","article-title":"Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: analysis of prognosis","volume":"25","author":"Ohshima","year":"2004","journal-title":"Int J Oncol"},{"issue":"24","key":"2023072117502244100_bib8","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","article-title":"Treatment and survival among 1594 patients with ATL","volume":"126","author":"Katsuya","year":"2015","journal-title":"Blood"},{"key":"2023072117502244100_bib9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2017.10.007","article-title":"Cutaneous T-cell lymphomas: focusing on novel agents in relapsed and refractory disease","volume":"61","author":"Argnani","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"2023072117502244100_bib10","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/imt.14.94","article-title":"Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas","volume":"6","author":"Remer","year":"2014","journal-title":"Immunotherapy"},{"issue":"5","key":"2023072117502244100_bib11","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-09-2697","article-title":"Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia\/lymphoma","volume":"16","author":"Ishii","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2023072117502244100_bib12","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","article-title":"Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma","volume":"125","author":"Duvic","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2023072117502244100_bib13","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2023072117502244100_bib14","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2023072117502244100_bib15","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"issue":"16","key":"2023072117502244100_bib16","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2023072117502244100_bib17","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"2023072117502244100_bib18","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2023072117502244100_bib19","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2023072117502244100_bib20","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A\u00a0T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2023072117502244100_bib21","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2023072117502244100_bib22","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"2023072117502244100_bib23","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ymthe.2018.10.001","article-title":"CD7 CAR T cells for the therapy of acute myeloid leukemia","volume":"27","author":"Gomes-Silva","year":"2019","journal-title":"Mol Ther"},{"issue":"25","key":"2023072117502244100_bib24","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","article-title":"Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies","volume":"1","author":"Png","year":"2017","journal-title":"Blood Adv"},{"issue":"8","key":"2023072117502244100_bib25","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR\u2013Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat Biotechnol"},{"issue":"6","key":"2023072117502244100_bib26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/ahg.12271","article-title":"CRISPR-Cas9: a cornerstone for the evolution of precision medicine","volume":"82","author":"Razzouk","year":"2018","journal-title":"Ann Hum Genet"},{"issue":"1","key":"2023072117502244100_bib27","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1186\/s12967-022-03797-7","article-title":"Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R\/R-AML)","volume":"20","author":"Lu","year":"2022","journal-title":"J\u00a0Transl Med"},{"issue":"9","key":"2023072117502244100_bib28","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/ajh.24794","article-title":"Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies","volume":"92","author":"Perera","year":"2017","journal-title":"Am J Hematol"},{"issue":"8","key":"2023072117502244100_bib29","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in\u00a0vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"issue":"7","key":"2023072117502244100_bib30","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol Ther"},{"issue":"7","key":"2023072117502244100_bib31","doi-asserted-by":"crossref","first-page":"e11867","DOI":"10.1371\/journal.pone.0011867","article-title":"A\u00a0simple and sensitive method for measuring tumor-specific T cell cytotoxicity","volume":"5","author":"Fu","year":"2010","journal-title":"PLoS One"},{"issue":"9","key":"2023072117502244100_bib32","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/nbt.3947","article-title":"An integrated expression atlas of miRNAs and their promoters in human and mouse","volume":"35","author":"de Rie","year":"2017","journal-title":"Nat Biotechnol"},{"issue":"11","key":"2023072117502244100_bib33","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1158\/1535-7163.MCT-12-0278","article-title":"Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells","volume":"11","author":"Chang","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2023072117502244100_bib34","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.immuni.2016.02.023","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"issue":"10","key":"2023072117502244100_bib35","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"2023072117502244100_bib36","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/cas.14069","article-title":"Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?","volume":"110","author":"Ohue","year":"2019","journal-title":"Cancer Sci"},{"issue":"3","key":"2023072117502244100_bib37","doi-asserted-by":"crossref","first-page":"911","DOI":"10.4049\/jimmunol.1402346","article-title":"Target antigen density governs the efficacy of anti-CD20-CD28-CD3 \u03b6 chimeric antigen receptor-modified effector CD8+ T cells","volume":"194","author":"Watanabe","year":"2015","journal-title":"J\u00a0Immunol"},{"issue":"11","key":"2023072117502244100_bib38","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1002\/eji.201848026","article-title":"Multifunctional cytokine production reveals functional superiority of memory CD4\u00a0T cells","volume":"49","author":"Westerhof","year":"2019","journal-title":"Eur J Immunol"},{"issue":"1","key":"2023072117502244100_bib39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.celrep.2017.09.015","article-title":"Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent","volume":"21","author":"Gomes-Silva","year":"2017","journal-title":"Cell Rep"},{"issue":"8","key":"2023072117502244100_bib40","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/exd.13261","article-title":"The biomarker landscape in mycosis fungoides and Sezary syndrome","volume":"26","author":"Dulmage","year":"2017","journal-title":"Exp Dermatol"},{"issue":"17","key":"2023072117502244100_bib41","doi-asserted-by":"crossref","first-page":"13884","DOI":"10.18632\/oncotarget.24490","article-title":"Structural considerations for functional anti-EGFR\u00a0\u00d7 anti-CD3 bispecific diabodies in light of domain order and binding affinity","volume":"9","author":"Asano","year":"2018","journal-title":"Oncotarget"},{"issue":"8","key":"2023072117502244100_bib42","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1158\/0008-5472.CAN-09-2824","article-title":"A\u00a0high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas","volume":"70","author":"Burns","year":"2010","journal-title":"Cancer Res"},{"issue":"1","key":"2023072117502244100_bib43","doi-asserted-by":"crossref","first-page":"8469","DOI":"10.1038\/s41598-022-12242-0","article-title":"Structure-guided affinity maturation of a novel human antibody targeting the SARS-CoV-2 nucleocapsid protein","volume":"12","author":"Wang","year":"2022","journal-title":"Sci Rep"},{"issue":"3","key":"2023072117502244100_bib44","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/leu.2015.311","article-title":"Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T\u00a0cells","volume":"30","author":"Pinz","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"2023072117502244100_bib45","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"issue":"2","key":"2023072117502244100_bib46","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1078-0432.CCR-14-0830","article-title":"Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive\/refractory mycosis fungoides and Sezary syndrome","volume":"21","author":"Ni","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2023072117502244100_bib47","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1084\/jem.20101876","article-title":"Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer","volume":"208","author":"De Monte","year":"2011","journal-title":"J\u00a0Exp Med"},{"issue":"1","key":"2023072117502244100_bib48","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4161\/onci.1.1.17939","article-title":"Cross-talk within the tumor microenvironment mediates Th2-type inflammation in pancreatic cancer","volume":"1","author":"Protti","year":"2012","journal-title":"Oncoimmunology"},{"issue":"6","key":"2023072117502244100_bib49","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/ijc.27784","article-title":"Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer","volume":"132","author":"Lin","year":"2013","journal-title":"Int J Cancer"},{"issue":"1","key":"2023072117502244100_bib50","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10549-010-0987-8","article-title":"An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer","volume":"127","author":"Mahmoud","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"2023072117502244100_bib51","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"issue":"9","key":"2023072117502244100_bib52","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/j.1464-410X.2010.09555.x","article-title":"Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma","volume":"107","author":"Liotta","year":"2011","journal-title":"BJU Int"},{"key":"2023072117502244100_bib53","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2018.01.022","article-title":"Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer","volume":"117","author":"Barua","year":"2018","journal-title":"Lung Cancer"},{"issue":"1","key":"2023072117502244100_bib54","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bjd.12641","article-title":"High expression of FOXP3 in primary melanoma is associated with tumour progression","volume":"170","author":"Gerber","year":"2014","journal-title":"Br J Dermatol"},{"issue":"10","key":"2023072117502244100_bib55","first-page":"13241","article-title":"Expression of Sirt1 and FoxP3 in classical Hodgkin lymphoma and tumor infiltrating lymphocytes: implications for immune dysregulation, prognosis and potential therapeutic targeting","volume":"8","author":"Quesada","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"issue":"24","key":"2023072117502244100_bib56","doi-asserted-by":"crossref","first-page":"39658","DOI":"10.18632\/oncotarget.17340","article-title":"Clinicopathologic and prognostic significance of regulatory T cells in patients with hepatocellular carcinoma: a meta-analysis","volume":"8","author":"Sun","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"2023072117502244100_bib57","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/iid3.136","article-title":"Transient Treg depletion enhances therapeutic anti-cancer vaccination","volume":"5","author":"Fisher","year":"2017","journal-title":"Immun Inflamm Dis"},{"issue":"11","key":"2023072117502244100_bib58","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1084\/jem.20130762","article-title":"Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy","volume":"210","author":"Bos","year":"2013","journal-title":"J\u00a0Exp Med"},{"issue":"19","key":"2023072117502244100_bib59","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1158\/1078-0432.CCR-15-0357","article-title":"Phase Ia study of FoxP3+ CD4 Treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients","volume":"21","author":"Kurose","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2023072117502244100_bib60","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/cas.12116","article-title":"Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia\/lymphoma","volume":"104","author":"Ishida","year":"2013","journal-title":"Cancer Sci"},{"issue":"3","key":"2023072117502244100_bib61","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ymthe.2017.01.011","article-title":"Inducible caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T\u00a0cells","volume":"25","author":"Diaconu","year":"2017","journal-title":"Mol Ther"},{"issue":"26","key":"2023072117502244100_bib62","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1182\/blood-2015-02-628354","article-title":"Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation","volume":"125","author":"Zhou","year":"2015","journal-title":"Blood"},{"issue":"17","key":"2023072117502244100_bib63","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2016-08-736041","article-title":"Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2023072117502244100_bib64","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1172\/JCI84813","article-title":"Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia","volume":"126","author":"Paszkiewicz","year":"2016","journal-title":"J\u00a0Clin Invest"},{"issue":"8","key":"2023072117502244100_bib65","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1158\/2326-6066.CIR-16-0043","article-title":"A\u00a0tet-On inducible system for controlling CD19-chimeric antigen receptor expression upon drug administration","volume":"4","author":"Sakemura","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"2023072117502244100_bib66","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJMra0707449","article-title":"Interleukin-17 and type 17 helper T cells","volume":"361","author":"Miossec","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2023072117502244100_bib67","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaci.2013.04.046","article-title":"Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis","volume":"132","author":"Su\u00e1rez-Fari\u00f1as","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/14\/3416\/2065376\/blooda_adv-2022-008327-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/14\/3416\/2065376\/blooda_adv-2022-008327-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T14:36:05Z","timestamp":1689950165000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/14\/3416\/495342\/Identifying-highly-active-anti-CCR4-CAR-T-cells"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":67,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,7,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008327","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742611967.793598441","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,12]]}}}